Evidence map›Paper›PMID 28151965›Full record

SynthesisPloS one2017

Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis.

Eliano P Navarese, Paul A Gurbel, Felicita Andreotti, Michalina Marta Kołodziejczak, Suetonia C Palmer, Sofia Dias, Antonino Buffon, Jacek Kubica, Mariusz Kowalewski, Tomasz Jadczyk and 9 more

Open access · goldAbstract readNetwork Meta-AnalysisSystematic Review
In one paragraph

Synthesis in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trimetazidine in Cardiovascular Disease and Beyond: A Comprehensive Review.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Observational
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 6 countries.

Eliano P NavareseDepartment of Cardiology, Multimedica IRCCS, Milan, Italy.
Paul A GurbelSystematic Investigation and Research on Interventions and Outcomes (SIRIO) MEDICINE research network, Milan, Italy.
Felicita AndreottiSystematic Investigation and Research on Interventions and Outcomes (SIRIO) MEDICINE research network, Milan, Italy.
Michalina Marta KołodziejczakSystematic Investigation and Research on Interventions and Outcomes (SIRIO) MEDICINE research network, Milan, Italy.
Suetonia C PalmerDepartment of Medicine, University of Otago Christchurch, Christchurch, New Zealand.
Sofia DiasSystematic Investigation and Research on Interventions and Outcomes (SIRIO) MEDICINE research network, Milan, Italy.
Antonino BuffonSystematic Investigation and Research on Interventions and Outcomes (SIRIO) MEDICINE research network, Milan, Italy.
Jacek KubicaDepartment of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Mariusz KowalewskiDepartment of Cardiac Surgery, Dr Antoni Jurasz Memorial University Hospital, Bydgoszcz, Poland.
Tomasz JadczykSystematic Investigation and Research on Interventions and Outcomes (SIRIO) MEDICINE research network, Milan, Italy.
Michał LaskiewiczSystematic Investigation and Research on Interventions and Outcomes (SIRIO) MEDICINE research network, Milan, Italy.
Marek JędrzejekSystematic Investigation and Research on Interventions and Outcomes (SIRIO) MEDICINE research network, Milan, Italy.
Maximillian BrockmeyerSystematic Investigation and Research on Interventions and Outcomes (SIRIO) MEDICINE research network, Milan, Italy.
Flavio AiroldiDepartment of Cardiology, Multimedica IRCCS, Milan, Italy.
Marinella RuospoDiaverum Medical Scientific Office, Diaverum Sweden AB, Lund, Sweden.
Stefano De ServiDepartment of Cardiology, Multimedica IRCCS, Milan, Italy.
Wojciech WojakowskiSystematic Investigation and Research on Interventions and Outcomes (SIRIO) MEDICINE research network, Milan, Italy.
Christopher O' ConnorSystematic Investigation and Research on Interventions and Outcomes (SIRIO) MEDICINE research network, Milan, Italy.
Giovanni F M StrippoliDiaverum Medical Scientific Office, Diaverum Sweden AB, Lund, Sweden.
Medical University of Silesia · PLMultiMedica · ITNicolaus Copernicus University · PLUniversità Cattolica del Sacro Cuore · ITAntoni Jurasz University Hospital · PLHeinrich Heine University Düsseldorf · DEUniversity of Bari Aldo Moro · ITUniversity of Bristol · GBUniversity of Otago · NZUniversity of Silesia in Katowice · PL

Funding

Medical Research Council MR/M005232/1
6 · The paper itself

Abstract

backgroundInterventional diagnostic and therapeutic procedures requiring intravascular iodinated contrast steadily increase patient exposure to the risks of contrast-induced acute kidney injury (CIAKI), which is associated with death, nonfatal cardiovascular events, and prolonged hospitalization. The aim of this study was to investigate the efficacy of pharmacological and non-pharmacological treatments for CIAKI prevention in patients undergoing cardiovascular invasive procedures with iodinated contrast. METHODS AND

findingsMEDLINE, Google Scholar, EMBASE and Cochrane databases as well as abstracts and presentations from major cardiovascular and nephrology meetings were searched, up to 22 April 2016. Eligible studies were randomized trials comparing strategies to prevent CIAKI (alone or in combination) when added to saline versus each other, saline, placebo, or no treatment in patients undergoing cardiovascular invasive procedures with administration of iodinated contrast. Two reviewers independently extracted trial-level data including number of patients, duration of follow-up, and outcomes. Eighteen strategies aimed at CIAKI prevention were identified. The primary outcome was the occurrence of CIAKI. Secondary outcomes were mortality, myocardial infarction, dialysis and heart failure. The data were pooled using network meta-analysis. Treatment estimates were calculated as odds ratios (ORs) with 95% credible intervals (CrI). 147 RCTs involving 33,463 patients were eligible. Saline plus N-acetylcysteine (OR 0.72, 95%CrI 0.57-0.88), ascorbic acid (0.59, 0.34-0.95), sodium bicarbonate plus N-acetylcysteine (0.59, 0.36-0.89), probucol (0.42, 0.15-0.91), methylxanthines (0.39, 0.20-0.66), statin (0.36, 0.21-0.59), device-guided matched hydration (0.35, 0.12-0.79), prostaglandins (0.26, 0.08-0.62) and trimetazidine (0.26, 0.09-0.59) were associated with lower odds of CIAKI compared to saline. Methylxanthines (0.12, 0.01-0.94) or left ventricular end-diastolic pressure-guided hydration (0.09, 0.01-0.59) were associated with lower mortality compared to saline.

conclusionsCurrently recommended treatment with saline as the only measure to prevent CIAKI during cardiovascular procedures may not represent the optimal strategy. Vasodilators, when added to saline, may significantly reduce the odds of CIAKI following cardiovascular procedures.

Indexed as

Acute Kidney InjuryContrast MediaDiagnostic Techniques, CardiovascularHumansKidney Function TestsRadiography, InterventionalVasodilator AgentsContrast MediaVasodilator Agents

Identifiers

PMID28151965
PMCPMC5289438
OpenAlexW2584407743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.